Work

19P Pharmacodynamic activity of [18F]-fluorthanatrace poly(ADP-ribose) polymerase (PARP) PET in BRCA1/2-mutated breast cancer patients receiving talazoparib

Year: 2024

Type: article

Abstract: PARP (poly-ADP ribose) inhibitors have been approved for a variety of solid tumors including breast, ovarian, and prostate cancers. We evaluated a novel positron emission tomography(PET) tracer 18F-fluorthanatrace (FTT), a radiolabeled analogue of PARP inhibitors. Uptake with 18F-FTT has been shown to correlate with ex vivo tumor measures of PARP1 in prior studies.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2024.102350

Authors: L. Lin, F. Wong, T.A. Yap, J.K. Litton

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,730